Cellceutix initiates patient enrollment in anti-cancer drug trials

Patients with advanced solid tumors are being recruited in clinical trials at Harvard University’s Dana-Farber Cancer Institute and partner Beth Israel Deaconess Medical Center.

Cellceutix chief scientific officer Dr. Krishna Menon said the first patients will begin therapy with Kevetrin in a matter of days.

"Not only is this is a substantial milestone for Cellceutix and its shareholders, but we feel it is important to the field of oncology," Dr. Menon added.

Kevetrin’s mechanism of action studies indicate the candidate’s ability to affect both wild and mutant types of p53 (guardian angel gene), induce apoptosis and activate Caspase 3 and cleavage of PARP.

Apoptosis is also induced by p53 activation, by inducing the expression of p53 target gene PUMA.

Cellceutix chief executive officer Leo Ehrlich said, "Because of the p53 connection and strong possibilities for Kevetrin, many people overlook how impactful and valuable Prurisol can be as well."